CROSSJECT appoints Lionel Seltz as Chief Financial Officer
Globenewswire·2026-03-25 17:00
DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO® needle-free auto-injector platform, notably ZEPIZURE® for the emergency treatment of epileptic seizures, today announces the appointment of Lionel Seltz as Chief Financial Officer. Before joining CROSSJECT, Lionel Seltz served as CFO North Europe at Antech Diagnostics, where he led finance across several countri ...